Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07503028
EARLY_PHASE1

An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

Sponsor: Celregen Therapeutics

View on ClinicalTrials.gov

Summary

This study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in patients with type 1 diabetes mellitus (T1DM) or pancreatogenic diabetes who have hypoglycemia unawareness or severe hypoglycemic events.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-10-17

Completion Date

2028-01-18

Last Updated

2026-03-31

Healthy Volunteers

No

Interventions

DRUG

CRG002

Intraportal infusion or Implantation underneath the abdominal anterior rectus sheat

Locations (1)

The First Affiliated Hospital of Anhui Medicaluniversity

Hefei, Anhui, China